These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 22749603)
1. Modifying the thermostability of inactivated influenza vaccines. Bliu A; Lemieux M; Li C; Li X; Wang J; Farnsworth A Vaccine; 2012 Aug; 30(37):5506-11. PubMed ID: 22749603 [TBL] [Abstract][Full Text] [Related]
2. Inactivated influenza vaccine stress can affect in vitro potency assay relationship to immunogenicity. Wen Y; Palladino G; Xie Y; Ferrari A; Settembre EC Vaccine; 2018 May; 36(21):3010-3017. PubMed ID: 29680201 [TBL] [Abstract][Full Text] [Related]
3. The stability and immunogenicity of inactivated MDCK cell-derived influenza H7N9 viruses. Tzeng TT; Lai CC; Weng TC; Cyue MH; Tsai SY; Tseng YF; Sung WC; Lee MS; Hu AY Vaccine; 2019 Nov; 37(47):7117-7122. PubMed ID: 31383484 [TBL] [Abstract][Full Text] [Related]
4. Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain. Farnsworth A; Cyr TD; Li C; Wang J; Li X Vaccine; 2011 Feb; 29(8):1529-33. PubMed ID: 21211583 [TBL] [Abstract][Full Text] [Related]
5. Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies. Verma S; Soto J; Vasudevan A; Schmeisser F; Alvarado-Facundo E; Wang W; Weiss CD; Weir JP PLoS One; 2017; 12(4):e0175733. PubMed ID: 28423025 [TBL] [Abstract][Full Text] [Related]
6. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination. Schmeisser F; Vodeiko GM; Lugovtsev VY; Stout RR; Weir JP Vaccine; 2010 Mar; 28(12):2442-9. PubMed ID: 20074687 [TBL] [Abstract][Full Text] [Related]
7. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102 [TBL] [Abstract][Full Text] [Related]
8. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. Treanor JJ; Schiff GM; Couch RB; Cate TR; Brady RC; Hay CM; Wolff M; She D; Cox MM J Infect Dis; 2006 May; 193(9):1223-8. PubMed ID: 16586358 [TBL] [Abstract][Full Text] [Related]
9. The impact of key amino acid substitutions in the hemagglutinin of influenza A (H3N2) viruses on vaccine production and antibody response. Chen Z; Zhou H; Jin H Vaccine; 2010 May; 28(24):4079-85. PubMed ID: 20399830 [TBL] [Abstract][Full Text] [Related]
10. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e. Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216 [TBL] [Abstract][Full Text] [Related]
11. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Brett IC; Johansson BE Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702 [TBL] [Abstract][Full Text] [Related]
12. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia. Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232 [TBL] [Abstract][Full Text] [Related]
13. Trends in development of the influenza vaccine with broader cross-protection. Stropkovská A; Janulíková J; Varecková E Acta Virol; 2010; 54(1):7-19. PubMed ID: 20201609 [TBL] [Abstract][Full Text] [Related]
14. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old. Keitel WA; Treanor JJ; El Sahly HM; Gilbert A; Meyer AL; Patriarca PA; Cox MM Vaccine; 2009 Dec; 28(2):379-85. PubMed ID: 19879222 [TBL] [Abstract][Full Text] [Related]
15. New DIVA vaccine for the protection of poultry against H5 highly pathogenic avian influenza viruses irrespective of the N-subtype. Peeters B; de Boer SM; Tjeerdsma G; Moormann R; Koch G Vaccine; 2012 Nov; 30(49):7078-83. PubMed ID: 23036502 [TBL] [Abstract][Full Text] [Related]
16. Single dose of oil-adjuvanted inactivated vaccine protects chickens from lethal infections of highly pathogenic H5N1 influenza virus. Hwang SD; Kim HS; Cho SW; Seo SH Vaccine; 2011 Mar; 29(11):2178-86. PubMed ID: 21172378 [TBL] [Abstract][Full Text] [Related]